Beckman Coulter Life Sciences (Nyon, Switzerland) has announced that it has acquired Blue Ocean Biomedical (Pembroke Pines, Florida, USA), a manufacturer of automated flow cytometry systems and reagents.
Beckman Coulter Life Sciences (Nyon, Switzerland) has announced that it has acquired Blue Ocean Biomedical (Pembroke Pines, Florida, USA), a manufacturer of automated flow cytometry systems and reagents.
The deal provides Beckman Coulter Life Sciences with low complexity analysers that integrate automated sample preparation and address emerging flow cytometry market trends to a broader global market. Blue Ocean Biomedical products complement Beckman's cytometry portfolio with instruments based on a 'sample in, result out' (SIRO) approach.
Scott Atkin, president, Beckman Coulter Life Sciences, commented, “This acquisition provides both immediate opportunity and long-term value. We'll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”
Mike Brochu, CEO and co-founder of Blue Ocean Biomedical, said, “Our team has developed a line of truly unique instrument systems. With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”
For more information please visit www.beckmancoulter.com
Assessing Safety of Medications During Pregnancy and Breastfeeding with LC–MS/MS
Published: April 8th 2025 | Updated: April 8th 2025Researchers conducted a study on medications used in psychiatry and neurology during the perinatal period, assessing how antiepileptic drugs (AEDs) affect placental functions, including transport mechanisms, nutrient transport, and trophoblast differentiation. Several quantitative methods, such as those for antianxiety and hypnotic drugs, were established to evaluate the safety of pharmacotherapy during breastfeeding using liquid chromatography-tandem mass spectrometry (LC–MS/MS).